J. Garcia-Corbacho

发表

Liquid biopsies come of age: towards implementation of circulating tumour DNA

James D. Brenton, Carlos Caldas, Jonathan C. M. Wan, 2017, Nature Reviews Cancer.

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

R. Bernards, C. Caldas, Mariette Schrier, 2017 .

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa L. Johnson, A. El-Khoueiry, J. Rodon, 2021, Clinical Cancer Research.

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

B. Clotet, J. Martinez-Picado, J. Prado, 2020, JAMA oncology.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.

Electronic health records and patient registries in medical oncology departments in Spain

N. Ribelles, C. Jara, J. Chacón, 2021, Clinical and Translational Oncology.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

J. Machiels, R. Mathijssen, M. D. de Jonge, 2016, Cancer Chemotherapy and Pharmacology.

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

R. Plummer, O. Pardo, M. Seckl, 2022, Nature Communications.

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2021, Journal of Clinical Oncology.

Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.

B. Clotet, J. Martinez-Picado, C. Brander, 2019, Journal of Clinical Oncology.

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer

A. Italiano, J. Bonneterre, M. Campone, 2019, Breast Cancer Research.

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

S. Barry, G. Shapiro, C. Higano, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhanced detection of circulating tumor DNA by fragment size analysis

Keval Patel, Richard Mair, Francesco Marass, 2018, Science Translational Medicine.

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA

N. Rosenfeld, D. Gale, F. Mouliere, 2021, Genome research.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

R. Plummer, M. Toulmonde, A. Italiano, 2018, European journal of cancer.

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

K. Yonemori, M. Beeram, S. Estrem, 2022, Journal of Clinical Oncology.

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

Tae Won Kim, H. Chung, N. Penel, 2022, Journal of Clinical Oncology.

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

M. Piccart, H. Wildiers, P. Tassone, 2020 .

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

M. Juan, B. Mellado, J. Llovet, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

Tae Won Kim, H. Chung, N. Penel, 2021, Journal of Clinical Oncology.

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

P. Kabos, C. Twelves, N. Turner, 2022, Journal of Clinical Oncology.

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

A. Cohen, U. Banerji, P. Kabos, 2021 .

A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.

U. Banerji, C. Twelves, R. Baird, 2020 .

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

F. Meric-Bernstam, P. LoRusso, J. Harding, 2020 .

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2022, Journal of Clinical Oncology.

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

O. Vasiljeva, G. V. van Dongen, F. Meric-Bernstam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

R. Plummer, E. D. de Vries, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

M. Juan, N. Viñolas, A. Prat, 2023, Cancer Immunology, Immunotherapy.

Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study

Juanita Lopez, S. Im, H. Chung, 2021 .

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

P. LoRusso, A. El-Khoueiry, A. Naing, 2019, Journal of Clinical Oncology.

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer

P. Jares, A. Prat, A. Vivancos, 2021, Frontiers in Oncology.

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

R. Plummer, E. Frenkel, A. Italiano, 2016 .

RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).

M. Seckl, I. Macpherson, D. Landers, 2017 .

Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors

M. Stumpp, M. Middleton, R. Baird, 2015 .

Liquid biopsies come of age: towards implementation of circulating tumour DNA

N. Rosenfeld, C. Caldas, J. Brenton, 2017, Nature Reviews Cancer.